EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies

Helena Hammarström iD, Anders Krifors, Simon Athlin, Vanda Friman, Karan Golestani, Anita Hällgren, Gisela Otto, Sara Oweling, Karlis Pauksens, Amelie Kinch, Ola Blennow

Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e1252-e1260

DOI: 10.1093/cid/ciac386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 20.05.2022. Verfasst von Helena Hammarström und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Pneumocystis carinii, Hematologic Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent studies have reported that reduced-dose trimethoprim-sulfamethoxazole (TMP-SMX) may be effective in the treatment of Pneumocystis jirovecii pneumonia (PJP), but data are lacking for patients with hematologic malignancies.

Methods

This retrospective study included all adult hematologic patients with PJP between 2013 and 2017 at 6 Swedish university hospitals. Treatment with 7.5–15 mg TMP/kg/day (reduced dose) was compared with >15–20 mg TMP/kg/day (standard dose), after correction for renal function. The primary outcome was the change in respiratory function (Δpartial pressure of oxygen [PaO2]/fraction of inspired oxygen [FiO2]) between baseline and day 8. Secondary outcomes were clinical failure and/or death at day 8 and death at day 30.

Results

Of a total of 113 included patients, 80 patients received reduced dose and 33 patients received standard dose. The overall 30-day mortality in the whole cohort was 14%. There were no clinically relevant differences in ΔPaO2/FiO2 at day 8 between the treatment groups, either before or after controlling for potential confounders in an adjusted regression model (−13.6 mm Hg [95% confidence interval {CI}, −56.7 to 29.5 mm Hg] and −9.4 mm Hg [95% CI, −50.5 to 31.7 mm Hg], respectively). Clinical failure and/or death at day 8 and 30-day mortality did not differ significantly between the groups (18% vs 21% and 14% vs 15%, respectively). Among patients with mild to moderate pneumonia, defined as PaO2/FiO2 >200 mm Hg, all 44 patients receiving the reduced dose were alive at day 30.

Conclusions

In this cohort of 113 patients with hematologic malignancies, reduced-dose TMP-SMX was effective and safe for treating mild to moderate PJP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, PneumocystisPneumocystis cariniiHematologic NeoplasmsAdultHumansTrimethoprim, Sulfamethoxazole Drug CombinationRetrospective Studies

Stichwörter der Autor:innen

Pneumocystis pneumoniahematologic malignanciestreatment outcometrimethoprim-sulfamethoxazole

Substanzen

Trimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Infectious Diseases, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Centre for Clinical Research Västmanland, Uppsala University, Uppsala, Sweden.
  • Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Department of Infectious Diseases, Skåne University Hospital, Malmö, Sweden.

ORCID-Profile: Helena Hammarström

Zitieren

APA

Hammarström, H., Krifors, A., Athlin, S., Friman, V., Golestani, K., Hällgren, A., Otto, G., Oweling, S., Pauksens, K., Kinch, A., & Blennow, O. (2023). Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies. Clinical Infectious Diseases, 76(3), e1252-e1260. https://doi.org/10.1093/cid/ciac386

Vancouver

Hammarström H, Krifors A, Athlin S, Friman V, Golestani K, Hällgren A, et al. Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies. Clinical Infectious Diseases. 2023;76(3):e1252-e1260. doi:10.1093/cid/ciac386

BibTeX
@article{Hammarstrm2023,
  author = {Hammarström, Helena and Krifors, Anders and Athlin, Simon and Friman, Vanda and Golestani, Karan and Hällgren, Anita and Otto, Gisela and Oweling, Sara and Pauksens, Karlis and Kinch, Amelie and Blennow, Ola},
  title = {Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {3},
  pages = {e1252--e1260},
  doi = {10.1093/cid/ciac386}
}
Kostenlos starten →